The FDA approval of the amended Phase 1 trial protocol for sudocetaxel zendusortide is a positive development for Theratechnologies. This approval allows the company to resume the trial, focusing on patients with ovarian cancer and refined patient selection. The successful development and eventual commercialization of sudocetaxel zendusortide could have a significant impact on the company's revenues and growth prospects, making this news likely to have a positive short-term impact on THTX stock.